Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma

RB1 mutations are seen in 40-60% of sporadic osteosarcoma. Here, the authors demonstrate a selective sensitivity to PARP inhibitors in RB1-mutated osteosarcoma-derived cell lines that is not associated with canonical signatures indicative of a homologous recombination defect.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Georgia Zoumpoulidou, Carlos Alvarez-Mendoza, Caterina Mancusi, Ritika-Mahmuda Ahmed, Milly Denman, Christopher D. Steele, Maxime Tarabichi, Errin Roy, Lauren R. Davies, Jiten Manji, Camilla Cristalli, Katia Scotlandi, Nischalan Pillay, Sandra J. Strauss, Sibylle Mittnacht
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/29d2b65339524853a5548dbf68b35ca4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/29d2b65339524853a5548dbf68b35ca4

Documents similaires